| pubmed-article:1425936 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1425936 | lifeskim:mentions | umls-concept:C0034721 | lld:lifeskim |
| pubmed-article:1425936 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:1425936 | lifeskim:mentions | umls-concept:C0085140 | lld:lifeskim |
| pubmed-article:1425936 | lifeskim:mentions | umls-concept:C0205145 | lld:lifeskim |
| pubmed-article:1425936 | lifeskim:mentions | umls-concept:C0120446 | lld:lifeskim |
| pubmed-article:1425936 | lifeskim:mentions | umls-concept:C0181496 | lld:lifeskim |
| pubmed-article:1425936 | pubmed:issue | 2-3 | lld:pubmed |
| pubmed-article:1425936 | pubmed:dateCreated | 1992-12-4 | lld:pubmed |
| pubmed-article:1425936 | pubmed:abstractText | Studies of 1,3-di-(2-[5-3H]tolyl)guanidine ([3H]DTG) binding to rat brain membranes revealed that [3H]DTG binds to a high and a low affinity site with Kd values of 19.8 nM and 1.31 microM (corresponding Bmax values 291 fmol/mg protein and 8.68 pmol/mg protein). The order of potency of competitors for [3H]DTG binding revealed a binding profile typical of sigma site ligands. Several sigma ligands such as the enantiomers of 3-PPP (3-(3-hydroxyphenyl)-N- (n-propyl)piperidine) and (+/-)-pentazocine exhibited biphasic competition profiles for [3H]DTG binding, whereas other sigma ligands such as haloperidol displayed monotonic competition curves. Neither phenytoin nor carbamazepine were observed to enhance [3H]DTG binding. These data support the hypothesis that multiple sigma binding sites exist. The lack of phenytoin and carbamazepine modulation of [3H]DTG binding are in agreement with the proposed greater density of sigma site 2 in the rat, since allosteric modulation has been ascribed to the DM1/sigma 1 site. | lld:pubmed |
| pubmed-article:1425936 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1425936 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1425936 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1425936 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1425936 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1425936 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1425936 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1425936 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1425936 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1425936 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1425936 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1425936 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1425936 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1425936 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:1425936 | pubmed:issn | 0014-2999 | lld:pubmed |
| pubmed-article:1425936 | pubmed:author | pubmed-author:ShankR PRP | lld:pubmed |
| pubmed-article:1425936 | pubmed:author | pubmed-author:CoddE EEE | lld:pubmed |
| pubmed-article:1425936 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1425936 | pubmed:day | 7 | lld:pubmed |
| pubmed-article:1425936 | pubmed:volume | 217 | lld:pubmed |
| pubmed-article:1425936 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1425936 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1425936 | pubmed:pagination | 149-52 | lld:pubmed |
| pubmed-article:1425936 | pubmed:dateRevised | 2003-11-14 | lld:pubmed |
| pubmed-article:1425936 | pubmed:meshHeading | pubmed-meshheading:1425936-... | lld:pubmed |
| pubmed-article:1425936 | pubmed:meshHeading | pubmed-meshheading:1425936-... | lld:pubmed |
| pubmed-article:1425936 | pubmed:meshHeading | pubmed-meshheading:1425936-... | lld:pubmed |
| pubmed-article:1425936 | pubmed:meshHeading | pubmed-meshheading:1425936-... | lld:pubmed |
| pubmed-article:1425936 | pubmed:meshHeading | pubmed-meshheading:1425936-... | lld:pubmed |
| pubmed-article:1425936 | pubmed:meshHeading | pubmed-meshheading:1425936-... | lld:pubmed |
| pubmed-article:1425936 | pubmed:meshHeading | pubmed-meshheading:1425936-... | lld:pubmed |
| pubmed-article:1425936 | pubmed:meshHeading | pubmed-meshheading:1425936-... | lld:pubmed |
| pubmed-article:1425936 | pubmed:meshHeading | pubmed-meshheading:1425936-... | lld:pubmed |
| pubmed-article:1425936 | pubmed:meshHeading | pubmed-meshheading:1425936-... | lld:pubmed |
| pubmed-article:1425936 | pubmed:meshHeading | pubmed-meshheading:1425936-... | lld:pubmed |
| pubmed-article:1425936 | pubmed:meshHeading | pubmed-meshheading:1425936-... | lld:pubmed |
| pubmed-article:1425936 | pubmed:meshHeading | pubmed-meshheading:1425936-... | lld:pubmed |
| pubmed-article:1425936 | pubmed:meshHeading | pubmed-meshheading:1425936-... | lld:pubmed |
| pubmed-article:1425936 | pubmed:meshHeading | pubmed-meshheading:1425936-... | lld:pubmed |
| pubmed-article:1425936 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1425936 | pubmed:articleTitle | 1,3-Di(2-[5-3H]tolyl)guanidine labels more than one site in rat forebrain. | lld:pubmed |
| pubmed-article:1425936 | pubmed:affiliation | Drug Discovery Research, R.W. Johnson Pharmaceutical Research Institute, Spring House, PA 19477-0776. | lld:pubmed |
| pubmed-article:1425936 | pubmed:publicationType | Journal Article | lld:pubmed |
